Astrazeneca PLC (AZN)
AstraZeneca is a pharmaceutical company that develops and sells prescription medicines for cancer, heart, lung and other diseases. It last closed at $174.35 on Nov 20, down 0.60% on the day. Over the last 12 months AZN insiders bought $3K of stock on the open market and sold $2.2M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From AZN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 24). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on AZN
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 3% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the swing low (Jun 18) at $173.66, and the nearest resistance the swing high (Jul 29) at $175.03.
| RSI (14) | 44.20 | Middle of its range | Neutral |
| MACD | 2.42 | Below its signal line | Bearish |
| Stochastic | 4.1 | Near the bottom of its range | Oversold |
| ADX (14) | 21.5 | Weak trend | |
| Williams %R | -98.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -77.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −6.5% | Change over 10 sessions | Bearish |
| ATR (14) | $4.06 | Typical daily range, 2.3% of price |
| RSI (14) | 49.75 | Middle of its range | Neutral |
| MACD | -1.88 | Above its signal line | Bullish |
| Stochastic | 71.9 | Middle of its range | Neutral |
| ADX (14) | 14.4 | No clear trend | |
| Williams %R | -47.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 93.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +8.8% | Change over 10 sessions | Bullish |
| ATR (14) | $10.72 | Typical daily range, 6.2% of price |
What happened before
See how AZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options FlowPrices may be delayed
90DNo whale options trades in AZN in the last 90 days.
Dark PoolPrices may be delayed
30DAZN Institutional Ownership
Full report →- ●681 buying vs 697 selling
- ▼Shares held by funds -3.2%
- ▼Funds holding -65
- ▲Superinvestors: 5 added, 0 cut
- ▲Put/call 4.27 to 0.43
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 1,452 | 1,517 | −4.3% |
| In funds' top 10 | 48 | 58 | −17.2% |
| Held by funds | – | – | – |
| New / increased | 138 / 543 | 272 / 514 | −13.4% |
| Reduced / sold out | 513 / 184 | 473 / 147 | +12.4% |
| Put/call ratio | 0.43 | 4.27 | −89.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AZN Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 8 | Mani SharmaSee Remarks | Buy | 20 | $160.57 | $3K |
| May 20 | Mani SharmaSee Remarks | Sale | 11,893 | $185.78 | $2.2M |
From SEC Form 4 filings by AZN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AZN is in one of them and how their past AZN trades turned out.
AZN News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AZN in an article yet. Here's the latest on the wider market.
AZN Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Alan ArmstrongR · OK | Buy | $1K – $15K | Mar 31, 2026 | Jul 21, 2026 | 112 d |
| Alan ArmstrongR · OK | Buy | $15K – $50K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Julia LetlowR · LA | Buy | $1K – $15K | Dec 8, 2025 | Jan 13, 2026 | 36 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Dec 18, 2025 | Jan 12, 2026 | 25 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Nov 19, 2025 | Dec 15, 2025 | 26 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Astrazeneca
AstraZeneca is a pharmaceutical company based in Cambridge that researches, develops and sells prescription medicines. Its work covers several therapy areas, including cancer, heart, kidney and metabolic disease, respiratory and immune conditions, rare diseases, and vaccines. Much of its research focuses on new treatments still in clinical trials, which it develops alone or with partners. Its medicines are aimed at patients and the healthcare providers who treat them.
- Headquarters
- Cambridge
- Founded
- 1913
- Website
- astrazeneca.com ↗










